GlassScriptPhysician profile
Janel R Harting
NPI 1821214560
$2,631.96
in general payments reported to CMS, 2019-2025
27 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $198 · 2021: $265 · 2022: $198 · 2023: $423 · 2024: $715 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.20 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.13 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $477.33 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $396.89 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.06 | 2022-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $159.26 | 2019-2024 | Uptravi, Opsumit |
| Grifols USA, LLC | $91.26 | 2020-2025 | Prolastin-C Liquid |
| Insmed, INC. | $82.35 | 2020-2025 | Brinsupri, Arikayce |
| Genentech USA, INC. | $71.30 | 2019-2023 | Xolair |
| Electromed, INC. | $57.52 | 2024-2025 | Smartvest |
| Amgen INC. | $52.75 | 2024-2025 | Tezspire |
| Resmed Corp | $37.13 | 2024-2025 | |
| Gilead Sciences, INC. | $35.26 | 2024 | |
| Viatris Specialty LLC | $33.20 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $31.22 | 2023 | Dupixent |
| 3b Medical, INC. | $25.11 | 2023 | Luna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.59 | 2019-2020 | |
| Apria Healthcare LLC | $20.57 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.81 | 2023 | Xywav |
| United Therapeutics Corporation | $19.40 | 2023 | Tyvaso |
| Vapotherm INC | $18.24 | 2022 | |
| Pfizer INC. | $17.13 | 2025 | |
| Mylan Specialty L.P. | $17.06 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.78 | 2025 | |
| Advanced Respiratory, INC | $15.72 | 2019 | |
| Abbvie INC. | $13.75 | 2021 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janel Harting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.